Literature DB >> 17602866

The next generation of PPAR drugs: do we have the tools to find them?

Barry G Shearer1, Andrew N Billin.   

Abstract

Agonists of PPARalpha and PPARgamma are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARbeta/delta are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17602866     DOI： 10.1016/j.bbalip.2007.05.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  26 in total

Review 1.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.

Authors:  Amanda Karolina Soares Silva; Christina Alves Peixoto
Journal:  Cell Mol Life Sci       Date:  2018-05-22       Impact factor: 9.261

2.  N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.

Authors:  Kavita Bhalla; Bor Jang Hwang; Jang Hyun Choi; Ruby Dewi; Lihui Ou; John Mclenithan; William Twaddel; Edwin Pozharski; Jeffry Stock; Geoffrey D Girnun
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

Review 3.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

4.  Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.

Authors:  Stephanie N Lewis; Zulma Garcia; Raquel Hontecillas; Josep Bassaganya-Riera; David R Bevan
Journal:  J Comput Aided Mol Des       Date:  2015-01-24       Impact factor: 3.686

5.  Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors.

Authors:  Tengis S Pavlov; John D Imig; Alexander Staruschenko
Journal:  PPAR Res       Date:  2010-06-14       Impact factor: 4.964

6.  MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.

Authors:  Francine M Gregoire; Fang Zhang; Holly J Clarke; Thomas A Gustafson; Dorothy D Sears; Svetlana Favelyukis; James Lenhard; Dennis Rentzeperis; L Edward Clemens; Yi Mu; Brian E Lavan
Journal:  Mol Endocrinol       Date:  2009-04-23

Review 7.  Fat and bone interactions.

Authors:  Sandra Bermeo; Krishanthi Gunaratnam; Gustavo Duque
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

Review 8.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

9.  Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities.

Authors:  Jane A Pinaire; Anne Reifel Miller; Francine M Gregoire
Journal:  PPAR Res       Date:  2009-03-23       Impact factor: 4.964

10.  Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation.

Authors:  Laura Guasch; Esther Sala; Anna Castell-Auví; Lidia Cedó; Klaus R Liedl; Gerhard Wolber; Markus Muehlbacher; Miquel Mulero; Montserrat Pinent; Anna Ardévol; Cristina Valls; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.